(S (NP-SBJ (JJ T-cell-directed) (NN TAL-1) (NN expression)) (VP (VBZ induces) (NP (NN T-cell) (NNS malignancies)) (PP (IN in) (NP (JJ transgenic) (NNS mice)))) (. .))
(S (NP-SBJ (DT The) (NN TAL-1) (NN gene)) (VP (VBZ specifies) (PP (IN for) (NP (NP (DT a) (JJ basic) (JJ domain-helix-loop-helix) (NN protein)) (, ,) (SBAR (WHNP-63 (WDT which)) (S (NP-SBJ-64 (-NONE- *T*-63)) (VP (VBZ is) (VP (VBN involved) (NP (-NONE- *-64)) (PP (IN in) (NP (NP (DT the) (NN control)) (PP (IN of) (NP (JJ normal) (NN hematopoiesis)))))))))))) (. .))
(S (S (PP (IN In) (NP (JJ human) (NN pathology))) (, ,) (NP-SBJ-65 (DT the) (NN TAL-1) (NN gene) (NN product)) (VP (VBZ is) (VP (VBN expressed) (NP (-NONE- *-65)) (PP (IN in) (NP (NP (DT a) (JJ high) (NN percentage)) (PP (IN of) (NP (NN T-cell) (JJ acute) (JJ lymphoblastic) (NNS leukemias))))) (PP (IN in) (NP (DT the) (JJ pediatric) (NN age) (NN range))))) (: ;)) (S (ADVP (RB however)) (, ,) (NP-SBJ (PRP it)) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN established) (SBAR (IN whether) (S (NP-SBJ (DT the) (NN expression)) (VP (VBZ has) (NP (DT a) (JJ causal) (NN role)) (PP (IN in) (NP (NN oncogenesis))))))))) (. .)))
(S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP describe) (NP (NP (DT the) (NN phenotype)) (PP (IN of) (NP (NN mouse) (JJ transgenic) (NNS lines))) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN by) (S (NP-SBJ-67 (-NONE- *)) (VP (VBG inducing) (NP (NP (NN tal-1) (NN protein) (NN expression)) (PP (IN in) (NP (JJ lymphoid) (NNS tissues)))) (S (NP-SBJ (-NONE- *-67)) (VP (VBG using) (NP (DT the) (NN LCK) (NN promoter)))))))))) (. .))
(S (NP-SBJ-106 (NP (DT The) (NN survival) (NN rate)) (PP (IN of) (NP (NN tal-1) (JJ transgenic) (NNS animals)))) (VP (VBD was) (ADJP-PRD (RB much) (JJR lower)) (SBAR (IN as) (S (NP-SBJ-107 (-NONE- *-106)) (VP (VBN compared) (NP (-NONE- *-107)) (PP (IN with) (NP (NN control) (NNS mice))))))) (. .))
(S (NP-SBJ (JJ Histopathological) (NN analysis)) (VP (VBD revealed) (NP (NP (NNS lymphomas)) (PP (IN of) (NP (NN T-cell) (NN type))) (, ,) (VP (ADVP-TMP (RB often)) (VBG comprising) (NP (DT a) (JJ minor) (NN B-cell) (NN component))))) (. .))
(S (NP-SBJ (DT Some) (NNS mice)) (VP (VBD showed) (NP (JJ marked) (JJ splenic) (NN lymphocyte) (NN depletion))) (. .))
(S (NP-SBJ (JJ Primary) (NN lymphocyte) (NNS cultures)) (VP-COOD (VP (VBD showed) (NP (NP (JJ partial) (NN independence)) (PP (IN from) (NP (JJ exogenous) (NN growth) (NNS stimuli))))) (CC and) (VP (VBD increased) (NP (NP (NN resistance)) (PP (TO to) (NP (JJ low-serum) (NN apoptosis)))))) (. .))
(S (S (S (NP-SBJ (-NONE- *)) (VP (TO To) (VP (ADVP (RB further)) (VB unravel) (NP (DT the) (NN tal-1) (JJ oncogenic) (NN potential))))) (, ,) (NP-SBJ-68 (NP (DT a) (NN strain)) (PP (IN of) (NP (NN tal-1) (JJ transgenic) (NNS mice)))) (VP (VBD was) (VP (VBN crossbred) (NP (-NONE- *-68)) (PP (IN with) (NP (JJ (- p53-)) (NNS mice))))) (: ;)) (S-COOD (S (NP-SBJ-69 (NP (DT the) (NN survival) (NN rate)) (PP (IN in) (NP (DT these) (NNS animals)))) (VP (VBD was) (VP (VBN reduced) (NP-108 (-NONE- *-69)) (PP (IN by) (NP (QP (JJR more) (IN than) (NN one-half)))) (SBAR-TMP (WHADVP-70 (WRB when)) (S (NP-SBJ-109 (-NONE- *-108)) (VP (VBN compared) (NP (-NONE- *-109)) (PP (IN with) (NP (NP (DT that)) (PP (IN of) (NP (NN tal-1) (NNS mice))))) (ADVP (-NONE- *T*-70)))))))) (, ,) (CC and) (S (NP-SBJ (JJ histopathological) (NN analysis)) (VP (VBD revealed) (ADVP (RB exclusively)) (NP (NN T-cell) (NNS lymphomas)))) (. .)))
(S (NP-SBJ (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN TAL-1)) (, ,) (VP (VBN expressed) (NP (-NONE- *)) (PP (IN in) (NP (NN T) (NNS cells)))) (, ,)) (VP (VBZ is) (ADVP (FW per) (FW se)) (NP-PRD (NP (DT a) (JJ potent) (NN oncogene)) (, ,) (SBAR (WHNP-71 (WDT which)) (S (NP-SBJ (-NONE- *T*-71)) (VP (MD may) (VP (VB exert) (NP (DT a) (JJ key) (JJ leukemogenetic) (NN role)) (PP (IN in) (NP (NP (DT the) (NN majority)) (PP (IN of) (NP (NN T-cell) (JJ acute) (JJ lymphoblastic) (NNS leukemias)))))))))))))) (. .))
